<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>28(4)</volume><submitter>Li X</submitter><pubmed_abstract>The PB2 subunit of the influenza RNA-dependent RNA polymerase (RdRp) has been identified as a promising target for the treatment of influenza. To expand the chemical space of the known influenza polymerase PB2 inhibitor-pimodivir (formerly VX-787) and improve its pharmacokinetic profile, two pimodivir analogs containing 2,3-dihydro-imidazopyridine fragment (comp. &lt;b>I&lt;/b> and comp. &lt;b>II&lt;/b>) were designed, synthesized, and evaluated for anti-influenza virus activity. In the cytopathic effect (CPE) inhibition assay, comp. &lt;b>I&lt;/b> and comp. &lt;b>II&lt;/b> showed IC&lt;sub>50&lt;/sub> values of 0.07 and 0.09 μM for A/Puerto Rico/8/34 (H1N1) and 0.04 and 0.07 μM for A/Hong Kong/8/68 (H3N2), respectively. Protein-binding affinity assay results showed a concentration-dependent association and dissociatio</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pagination>1849</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960307</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Design, Synthesis, Biological Evaluation, and Molecular Dynamics Simulation of Influenza Polymerase PB2 Inhibitors.</pubmed_title><pmcid>PMC9960307</pmcid><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Che J</pubmed_authors><pubmed_authors>Cao R</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Zhao X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design, Synthesis, Biological Evaluation, and Molecular Dynamics Simulation of Influenza Polymerase PB2 Inhibitors.</name><description>The PB2 subunit of the influenza RNA-dependent RNA polymerase (RdRp) has been identified as a promising target for the treatment of influenza. To expand the chemical space of the known influenza polymerase PB2 inhibitor-pimodivir (formerly VX-787) and improve its pharmacokinetic profile, two pimodivir analogs containing 2,3-dihydro-imidazopyridine fragment (comp. &lt;b>I&lt;/b> and comp. &lt;b>II&lt;/b>) were designed, synthesized, and evaluated for anti-influenza virus activity. In the cytopathic effect (CPE) inhibition assay, comp. &lt;b>I&lt;/b> and comp. &lt;b>II&lt;/b> showed IC&lt;sub>50&lt;/sub> values of 0.07 and 0.09 μM for A/Puerto Rico/8/34 (H1N1) and 0.04 and 0.07 μM for A/Hong Kong/8/68 (H3N2), respectively. Protein-binding affinity assay results showed a concentration-dependent association and dissociatio</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-05-13T14:28:57.724Z</modification><creation>2025-02-19T03:26:40.054Z</creation></dates><accession>S-EPMC9960307</accession><cross_references><pubmed>36838837</pubmed><doi>10.3390/molecules28041849</doi></cross_references></HashMap>